Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2CNS 1

Conditions

Pheochromocytoma 2Neuroblastoma 1Endocrine System Diseases 1

Interventions

lutetium Lu 177 dotatate 31Magnetic Resonance Spectroscopy 25pembrolizumab 21Specimen Handling 18Nivolumab 17cabozantinib 14lenvatinib 12Everolimus 12trametinib 11gallium Ga 68 dotatate 10dabrafenib 10Ipilimumab 10Carboplatin 10Cisplatin 8atezolizumab 7Temozolomide 7Lutetium-177 7Capecitabine 7X-Rays 6Etoposide 6surufatinib 5olaparib 5lanreotide 5fluorodopa F 18 5cemiplimab 5Vemurafenib 5Paclitaxel 5Octreotide 5Lutetium 5Fluorodeoxyglucose F18 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
6-fluorodopamine × Endocrine × 1 year × Clear all
NCT00004847 2026-06-03

Diagnosis of Pheochromocytoma

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
3,000 enrolled
Endocrine

Endocrine System Diseases, Pheochromocytoma

NCT03541720 2026-04-29

18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma

St. Jude Children's Research Hospital

Phase EARLY_PHASE1 Active not recruiting
13 enrolled
CNSEndocrine

Neuroblastoma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡